Scholar Rock Holding マネジメント
マネジメント 基準チェック /24
Scholar Rock Holdingの CEO はDavid Hallalで、 Apr2025年に任命され、 の在任期間は 1.33年です。 の年間総報酬は$ 33.30Mで、 1.9%給与と98.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.33%を直接所有しており、その価値は$ 21.19M 。経営陣と取締役会の平均在任期間はそれぞれ2年と10.9年です。
主要情報
David Hallal
最高経営責任者
US$33.3m
報酬総額
| CEO給与比率 | 1.91% |
| CEO在任期間 | 1.3yrs |
| CEOの所有権 | 0.3% |
| 経営陣の平均在職期間 | 2yrs |
| 取締役会の平均在任期間 | 10.9yrs |
経営陣の近況
Recent updates
ナラティブ更新 • Jun 26
SRRK: Regulatory Resubmission And Trial Updates Will Shape Balanced Risk Profile
Scholar Rock Holding's analyst price target has moved higher to $59.31 from $55.07, with analysts pointing to updated assumptions on fair value, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent Street research on Scholar Rock Holding centers on updated price targets and reactions to regulatory milestones, giving you a clearer sense of how analysts are framing valuation, execution risk and potential growth corridors for the company.Seeking Alpha • Jun 25
Scholar Rock: New Treatment Boost For SMA Patients -- With September PDUFA
Summary Scholar Rock Holding Corporation (SRRK) focuses on Apitegromab, a selective anti-latent myostatin antibody for Spinal Muscular Atrophy in patients aged 2 and above. The initial FDA BLA submission for Apitegromab was rejected, but SRRK has since resubmitted its BLA for review. The investment thesis centers on regulatory progress and the clinical potential of Apitegromab in addressing unmet needs in SMA. SRRK's future hinges on successful FDA approval and market adoption of its lead therapy. Read the full article on Seeking Alpha分析記事 • Jun 21
Scholar Rock Holding (SRRK) Stock Could Be 14.1% Undervalued On Its SMA Narrative
Scholar Rock Holding (SRRK) stock has drawn investor attention after a recent move in its share price, with the company’s Nasdaq listing closing at $47.33 and showing mixed short and longer term return figures. See our latest analysis for Scholar Rock Holding. For context, Scholar Rock Holding’s recent 1-day share price return of 0.81% and 7-day share price return of 7.13% sit alongside a slightly weaker 30-day share price return, while its 1-year and 3-year total shareholder returns point to...新しいナラティブ • Mar 07
Muscle-Targeted SMA Therapies And Global Expansion Will Reshape Long-Term Outlook
Catalysts About Scholar Rock Holding Scholar Rock Holding focuses on developing muscle-targeted therapies for rare and severe neuromuscular diseases, led by its apitegromab program for spinal muscular atrophy and a broader anti myostatin pipeline. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 17
Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade
Summary Scholar Rock Holding Corporation's lead candidate, apitegromab, has shown promising efficacy in treating SMA and is awaiting FDA and EMA approval, with a potential market launch by late 2025. Apitegromab could achieve blockbuster status with peak revenue potential >$2.5bn, especially based on its ability to build muscle mass in combo with gene therapies like Spinraza and Zolgensma. Scholar Rock's obesity therapy potential with apitegromab and GLP-1 RA combo presents a high-risk, high-reward scenario, with significant upside if Phase 2 data is positive. Despite financial challenges and potential dilution, I upgrade SRRK stock to a "Buy" due to its promising pipeline and undervalued stock price at $30. Read the full article on Seeking AlphaSeeking Alpha • Jan 30
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Summary Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders. The global obesity drugs market is expected to reach $200 billion by 2031. Read the full article on Seeking AlphaSeeking Alpha • Dec 24
Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High
Summary Scholar Rock's lead candidate, apitegromab, showed promising Phase 3 results in SMA, boosting shares by over 325%, with plans for regulatory submissions in the US and EU. Despite positive data, Scholar Rock faces financial challenges, including significant net losses and limited cash, suggesting potential future fundraisings. The company is exploring apitegromab's potential in obesity treatment, with a Phase 2 study underway, in combo with a GLP-1 agonist drug - results are expected in Q2 2025. Given current valuation and financial risks, I recommend a "Hold" rating, with potential buying opportunities post-approval or pre-obesity study results if the share price dips below $30, I'd suggest. Read the full article on Seeking AlphaSeeking Alpha • Oct 07
Scholar Rock: SMA Program Strides Forward With Positive Clinical Data
Summary Apitegromab met the primary endpoint in its phase 3 SAPPHIRE study for spinal muscular atrophy, setting up BLA & MAA filings in Q1 2025. Apitegromab is the first treatment targeting muscle fiber atrophy in SMA, potentially changing the standard of care and offering a competitive edge. Scholar Rock also has apitegromab being explored in a phase 2 study for obesity, with clinical data expected in Q2 2025, presenting another catalyst. The spinal muscular atrophy market in the 7 major markets [7MM] is expected to reach $13 billion by 2034. Read the full article on Seeking AlphaSeeking Alpha • Jan 12
Scholar Rock: Solid Data And Good Prospects
Summary Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Phase 3 data expected in 4Q 2024. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$409m |
| Mar 31 2026 | n/a | n/a | -US$409m |
| Dec 31 2025 | US$33m | US$638k | -US$378m |
| Sep 30 2025 | n/a | n/a | -US$353m |
| Jun 30 2025 | n/a | n/a | -US$316m |
| Mar 31 2025 | n/a | n/a | -US$264m |
| Dec 31 2024 | US$401k | n/a | -US$246m |
| Sep 30 2024 | n/a | n/a | -US$226m |
| Jun 30 2024 | n/a | n/a | -US$204m |
| Mar 31 2024 | n/a | n/a | -US$183m |
| Dec 31 2023 | US$417k | n/a | -US$166m |
| Sep 30 2023 | n/a | n/a | -US$159m |
| Jun 30 2023 | n/a | n/a | -US$160m |
| Mar 31 2023 | n/a | n/a | -US$166m |
| Dec 31 2022 | US$316k | n/a | -US$135m |
| Sep 30 2022 | n/a | n/a | -US$131m |
| Jun 30 2022 | n/a | n/a | -US$125m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | US$315k | n/a | -US$132m |
| Sep 30 2021 | n/a | n/a | -US$122m |
| Jun 30 2021 | n/a | n/a | -US$109m |
| Mar 31 2021 | n/a | n/a | -US$97m |
| Dec 31 2020 | US$400k | n/a | -US$86m |
| Sep 30 2020 | n/a | n/a | -US$71m |
| Jun 30 2020 | n/a | n/a | -US$64m |
| Mar 31 2020 | n/a | n/a | -US$57m |
| Dec 31 2019 | US$303k | n/a | -US$51m |
報酬と市場: Davidの 総報酬 ($USD 33.30M ) は、 US市場 ($USD 8.19M ) の同規模の企業の平均を上回っています。
報酬と収益: Davidの報酬は増加しましたが、会社は利益を上げていません。
CEO
David Hallal (60 yo)
1.3yrs
在職期間
US$33,300,927
報酬
Mr. David L. Hallal is Chief Executive Officer of Scholar Rock, Inc. since April 27, 2025 and serves as its Chairman of the Board of Directors since July 2017. He had been its Executive Chairman since Apri...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 1.3yrs | US$33.30m | 0.33% $ 21.2m | |
| CFO & Treasurer | 1.3yrs | US$13.12m | 0.039% $ 2.5m | |
| Chief Operating Officer | 1.3yrs | US$13.16m | 0.039% $ 2.5m | |
| President of R&D | 1.3yrs | US$14.89m | 0.048% $ 3.1m | |
| Interim Principal Financial & Accounting Officer | 6.8yrs | データなし | 0.068% $ 4.3m | |
| Chief Technical & Quality Officer | 1.6yrs | データなし | データなし | |
| Chief Scientific Officer | 2.5yrs | US$2.96m | データなし | |
| Vice President of Corporate Affairs & Investor Relations | no data | データなし | データなし | |
| General Counsel & Corporate Secretary | 6.4yrs | US$2.13m | 0.11% $ 6.9m | |
| Chief Human Resources Officer | 5yrs | データなし | 0.071% $ 4.6m | |
| Senior Vice President of Human Resources | no data | データなし | データなし | |
| Senior Vice President of Clinical Development & Operations | 6.4yrs | データなし | データなし |
2.0yrs
平均在職期間
54yo
平均年齢
経験豊富な経営陣: SRRKの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.1yrs | US$33.30m | 0.33% $ 21.2m | |
| President of R&D | 12.6yrs | US$14.89m | 0.048% $ 3.1m | |
| Independent Director & Member of Scientific Advisory Board | 12.8yrs | US$531.05k | 0.043% $ 2.8m | |
| Member of Scientific Advisory Board | no data | US$48.97k | データなし | |
| Independent Director & Member of Scientific Advisory Board | 9.8yrs | US$540.66k | 0.017% $ 1.1m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 12yrs | US$531.05k | 0.089% $ 5.7m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.4yrs | US$540.05k | 0.010% $ 665.8k |
10.9yrs
平均在職期間
67yo
平均年齢
経験豊富なボード: SRRKの 取締役会 は経験豊富で 経験豊富 です ( 10.9年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/16 23:25 |
| 終値 | 2026/08/14 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Scholar Rock Holding Corporation 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25
| アナリスト | 機関 |
|---|---|
| Madhu Kumar | Baird |
| Etzer Darout | Barclays |
| Evan Seigerman | BMO Capital Markets Equity Research |